Davis Polk advised Goldman, Sachs & Co. and J.P. Morgan Securities LLC as representatives of the several underwriters in connection with an SEC-registered offering of 9,000,000 shares of common stock of Isis Pharmaceuticals, Inc. The gross proceeds from the offering were $171 million. The common stock is listed on The Nasdaq Global Select Market under the symbol “ISIS.”
Isis, headquartered in Carlsbad, California, is the leading company in antisense drug discovery and development, exploiting a novel drug discovery platform to generate a broad pipeline of first-in-class drugs with an emphasis on cardiovascular, metabolic, severe and rare diseases and cancer.
The Davis Polk corporate team included partner Alan F. Denenberg and associate Jeffrey Gould. The tax team included partner Rachel D. Kleinberg. Associate Bruce Rose-Innes provided intellectual property advice. Cassandra Aguirre was the legal assistant on the transaction. Members of the Davis Polk team are based in the Menlo Park and New York offices.
